Boan Biotech Nears Denosumab Registration After Phase III Enrollment Completion

Biosimilar Developer Is Nearing The Finish Line As Key Patents Are Set To Expire In 2025

 
• By Urtė Fultinavičiūtė
  
Two People Participating In A Clinical Trial
Boan Biotech’s denosumab biosimilar BA6101 is already approved in China • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products